Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dr. Adi Mor will deliver a prerecorded corporate presentation, which will be available from September 5, 2025, at 7:00 am ET for 90 days via webcast. The company's management team will also conduct one-on-one investor meetings on September 8-9, 2025.
Chemomab Therapeutics (Nasdaq: CMMB), una società biotech in fase clinica focalizzata sulle malattie fibro-infiammatorie, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference.
Il CEO Dott. Adi Mor presenterà una presentazione aziendale preregistrata, disponibile in webcast dal 5 settembre 2025 alle 7:00 ET per 90 giorni. Il team di gestione condurrà inoltre incontri individuali con gli investitori il 8 e 9 settembre 2025.
Chemomab Therapeutics (Nasdaq: CMMB), una empresa biotecnológica en fase clínica centrada en enfermedades fibroinflamatorias, anunció su participación en la H.C. Wainwright 27th Annual Global Investment Conference.
El CEO Dr. Adi Mor ofrecerá una presentación corporativa preregistrada, disponible en webcast desde el 5 de septiembre de 2025 a las 7:00 ET durante 90 días. El equipo directivo también realizará reuniones individuales con inversores los 8 y 9 de septiembre de 2025.
Chemomab Therapeutics (나스닥: CMMB)는 섬유성 염증 질환에 중점을 둔 임상 단계의 바이오텍 기업으로, H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다.
CEO인 Adi Mor 박사는 사전 녹화된 기업 프레젠테이션을 진행하며, 해당 발표는 2025년 9월 5일 오전 7:00(동부시간)부터 90일간 웹캐스트로 시청할 수 있습니다. 회사 경영진은 또한 2025년 9월 8–9일에 1:1 투자자 미팅을 진행할 예정입니다.
Chemomab Therapeutics (Nasdaq: CMMB), une société biotechnologique en phase clinique axée sur les maladies fibro‑inflammatoires, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference.
Le PDG Dr Adi Mor présentera une conférence d’entreprise préenregistrée, disponible en webcast à partir du 5 septembre 2025 à 7h00 ET pour une durée de 90 jours. L'équipe de direction tiendra également des rendez‑vous individuels avec des investisseurs les 8 et 9 septembre 2025.
Chemomab Therapeutics (Nasdaq: CMMB), ein klinisch tätiges Biotech-Unternehmen mit Schwerpunkt auf fibro‑entzündlichen Erkrankungen, gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference bekannt.
CEO Dr. Adi Mor wird eine vorab aufgezeichnete Unternehmenspräsentation halten, die ab dem 5. September 2025 um 7:00 Uhr ET für 90 Tage per Webcast abrufbar ist. Das Managementteam führt außerdem Einzelgespräche mit Investoren am 8. und 9. September 2025.
- None.
- None.
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 5, 2025 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website. Chemomab management will also be hosting 1x1 investor meetings during the conference on September 8 and September 9, 2025.
Chemomab Presentation at H.C. Wainwright 27th Annual Global Investment Conference
| Date: | September 5, 2025 |
| Time: | Available starting at 7:00 am ET for 90 days |
| Venue: | Virtual |
| Format: | Prerecorded webcast presentation |
| Webcast Link: | https://journey.ct.events/view/ac2a207f-54a8-4812-9d90-025b238d0eba |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug Phase 3 trial in patients with PSC. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When is Chemomab Therapeutics (CMMB) presenting at the H.C. Wainwright Conference?
Who will be presenting for Chemomab (CMMB) at the H.C. Wainwright Conference?
How can investors access Chemomab's (CMMB) presentation at the H.C. Wainwright Conference?
Will Chemomab (CMMB) management be available for meetings during the conference?
